UPenn
CHOP, Penn Get $14M NIH Grant to Develop Prime-Editing Treatments for Rare Metabolic Diseases
Researchers will develop therapies for urea cycle disorders and create a platform to rapidly develop treatments for other rare genetic disorders.
Hemogenyx to Use FLT3 Assay to Identify AML Patients for CAR T-Cell Trial
The firm expects to launch its Phase I trial of HEMO-CAR-T in FLT3-expressing AML patients at MD Anderson Cancer Center imminently.
Passage Bio Licenses Gene Therapy Programs to UPenn Spinout GemmaBio
Passage Bio cofounder James Wilson recently stepped down from his role directing UPenn's Gene Therapy Program to launch Gemma Biotherapeutics.
Verismo Therapeutics to Study SynKIR-310 in Phase I Lymphoma Trial
The FDA cleared the UPenn spinout's investigational new drug application, allowing it to study its autologous cell therapy in advanced non-Hodgkin lymphoma patients.
Sarepta Defeats Gene Therapy Patent Infringement Claims From Regenxbio, UPenn
Sarepta had been accused of using methods patented by UPenn and licensed by Regenxbio to create its DMD gene therapy.
Sep 18, 2023
Oct 17, 2022